"Immunosuppressive Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging.
| Descriptor ID |
D007166
|
| MeSH Number(s) |
D27.505.696.477.656
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Immunosuppressive Agents".
Below are MeSH descriptors whose meaning is more specific than "Immunosuppressive Agents".
This graph shows the total number of publications written about "Immunosuppressive Agents" by people in this website by year, and whether "Immunosuppressive Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 9 | 1 | 10 |
| 1996 | 22 | 14 | 36 |
| 1997 | 25 | 15 | 40 |
| 1998 | 36 | 12 | 48 |
| 1999 | 27 | 18 | 45 |
| 2000 | 14 | 12 | 26 |
| 2001 | 19 | 13 | 32 |
| 2002 | 8 | 5 | 13 |
| 2003 | 18 | 8 | 26 |
| 2004 | 13 | 15 | 28 |
| 2005 | 14 | 10 | 24 |
| 2006 | 19 | 13 | 32 |
| 2007 | 9 | 10 | 19 |
| 2008 | 8 | 13 | 21 |
| 2009 | 12 | 10 | 22 |
| 2010 | 13 | 13 | 26 |
| 2011 | 11 | 8 | 19 |
| 2012 | 12 | 11 | 23 |
| 2013 | 17 | 14 | 31 |
| 2014 | 18 | 9 | 27 |
| 2015 | 4 | 12 | 16 |
| 2016 | 13 | 9 | 22 |
| 2017 | 11 | 6 | 17 |
| 2018 | 8 | 7 | 15 |
| 2019 | 8 | 12 | 20 |
| 2020 | 7 | 10 | 17 |
| 2021 | 7 | 6 | 13 |
| 2022 | 1 | 7 | 8 |
| 2023 | 1 | 9 | 10 |
| 2024 | 5 | 8 | 13 |
| 2025 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Immunosuppressive Agents" by people in Profiles.
-
Evaluating Renal Disease in Pediatric-Onset Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Disease Course, Outcomes, and Predictors of Outcome. Arthritis Rheumatol. 2025 May; 77(5):606-614.
-
Impact of steroid-sparing immunosuppressive agents on tumor outcome in the context of cancer immunotherapy with highlight on melanoma: a systematic literature review and meta-analysis. Front Immunol. 2024; 15:1499478.
-
Comparing Rituximab and Cyclophosphamide in Induction Therapy for Childhood-Onset Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: An ARChiVe Registry Cohort Study. Arthritis Care Res (Hoboken). 2025 Apr; 77(4):504-512.
-
Impact of Letermovir for Cytomegalovirus Primary Prophylaxis on Myelosuppression and Immunosuppression in Lung Transplant Recipients. Clin Transplant. 2024 Dec; 38(12):e70033.
-
High-dose alemtuzumab and cyclosporine vs tacrolimus, methotrexate, and sirolimus for chronic graft-versus-host disease prevention. Blood Adv. 2024 08 27; 8(16):4294-4310.
-
Chromoblastomycosis: A Potential Mimic of Squamous Cell Carcinoma in Transplant Recipients. Transplant Proc. 2024 Jul-Aug; 56(6):1454-1456.
-
Mystery lung mass in a kidney transplant recipient. Transpl Infect Dis. 2024 08; 26(4):e14353.
-
Efficacy and Safety of Bleselumab in Preventing the Recurrence of Primary Focal Segmental Glomerulosclerosis in Kidney Transplant Recipients: A Phase 2a, Randomized, Multicenter Study. Transplantation. 2024 08 01; 108(8):1782-1792.
-
Cancer Surveillance in Solid Organ Transplant Recipients With a Pretransplant History of Malignancy: Multidisciplinary Collaborative Expert Opinion. Transplantation. 2024 12 01; 108(12):2336-2350.
-
Clinical associations with a polygenic predisposition to benign lower white blood cell counts. Nat Commun. 2024 Apr 22; 15(1):3384.